HD-OPM Archive
Topics › Brain health & dementia

Ezetimibe use linked to 86% lower Alzheimer's and dementia risk in database analysis

Louis Nervegna · Oct 19, 2026 · ♥ 38 reactions · 27 comments · original Facebook post
Brain health & dementiaPCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panel
AI summary & key facts

A 2024 Aging Biology paper analysed clinical databases and found that people taking the LDL-lowering drug ezetimibe had a much lower risk of Alzheimer's disease and related dementias. Brain tissue from patients also showed more of two proteins, HK1 and 14-3-3 gamma. This is an observational association, so it does not prove the drug prevents dementia.

Link to journal paper:

Paper · Aging Biol · 2024Ezetimibe Lowers Risk of Alzheimer's and Related Dementias over Sevenfold, Reducing Aggregation in Model Systems by Inhibiting 14-3-3G::Hexokinase Interaction.Numerous factors predispose to progression of cognitive impairment to Alzheimer's disease and related dementias (ADRD), most notably age, APOE(ε4) alleles, traumatic brain injury, heart disease, hypertension, obesity/diabetes, and Down's syndrome. Protein aggregation is diagnostic for neurodegenerative diseases, and may be causal through promotion of chronic neuroinflammation. We isolated aggregates from postmortem…pmc.ncbi.nlm.nih.gov

Link to accompanying editorial (by geroscientist Vera Gorbunova):

agingcelljournal.orgAging Biology | Hiding in Plain Sight: FDA-Approved Cholesterol Drug Ezetimibe as a Treatment for Alzheimer’sOur mission is to publish high quality research on the fundamental mechanisms of aging and longevity.agingcelljournal.org

#ezetimibeHD #dementiaHD #alzheimersHD

Research cited

Alzheimer’s disease is characterized by the progressive loss of memory and cognitive function, accompanied by the accumulation of abnormal proteins in the brain that contribute to neuronal damage and chronic inflammation. Researchers are increasingly investigating whether existing medications could influence these processes and potentially reduce the risk of neurodegenerative diseases.

A 2024 study published in Aging Biology examined ezetimibe, an FDA-approved cholesterol-lowering medication commonly prescribed to reduce LDL cholesterol.

By analyzing clinical databases, researchers found that ezetimibe use was associated with an 86% lower risk of Alzheimer's disease and related dementias, with an even greater reduction of more than 88% observed among high-risk individuals with heart disease.

The researchers also examined postmortem brain tissue and identified increased accumulation of two proteins, hexokinase-1 (HK1) and 14-3-3 gamma (14-3-3γ), in patients with Alzheimer's disease and heart disease compared with healthy controls.

May be an image of text
← newer: TMAO post: no text or details availableolder: Stanford experts say colonoscopy still matters despite a tri →